IQWiG comments

IQWiG also comments on general topics, for example, draft laws or scientific methods. You can find the comments issued by the Institute and joint comments written in cooperation with other institutions on this page.

Comments (in chronological order):

2025-05-05

The European Commission’s targeted evaluation of the strategy to support medical countermeasures against public health threats

Crisis resilience through evidence: Comment on the EU strategy for medical countermeasures against public health threats.

IQWiG welcomes the EU Commission's targeted evaluation of crisis preparedness and emphasizes the role of health technology assessment procedures. Rapid and living reviews can accelerate and strengthen evidence-based decisions, particularly in health emergencies – a crucial component for effective measures in serious situations.

view comment

2025-04-04

Scientific assessment of screening examinations for the detection of non-communicable diseases

In its comment, IQWiG welcomes the changes planned by the BMUV to the General Administrative Regulation and only suggests a few specific clarifications to the draft.

View comment

2025-04-01

Joint positions for better evidence in approval and benefit assessments

A key result of a workshop series of European regulatory authorities and HTA agencies: Drug studies should be designed in such a way that they address both regulatory questions and the essential research questions of benefit assessments.

to the position paper

2025-03-19

Evaluation of the EU rules on medical devices and in vitro diagnostics
Comment of Institute for Quality and Efficiency in Health Care (IQWiG) March 19th, 2025

2024-07-15

Position paper "Evidence base and easy/simple language" of the "Accessible Health Communication" department of the German Network for Health Literacy (DNGK).
Comment of 15 July 2024 by the Institute for Quality and Efficiency in Health Care (IQWiG) on the consultation version of 4 June 2024.

2012-12-05

IQWiG comment on the draft law of the Federal Government for advancing cancer screening and quality assurance using clinical cancer registries (Law on Cancer Screening and Registration – KFRG) Bundestag printed paper 17/11267 of 05.12.2012 (German version)

2012-10-25

Comment to AHRQ on: "Assessing confounding, the risk of bias and precision of observational studies of interventions or exposures: further development of the RTI Item Bank"

2012-09-13

Comment to AHRQ on: "A framework for assessing the strength of methodological recommendations for systematic review and meta-analysis"

2012-08-16

Comment on the proposal of the EU commission for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (German version)

2012-07-12

Comment on the draft of a law to implement the recommendations of the National Cancer Plan (Cancer Plan Implementation Law) (German version)

2012-06-26

IQWiG comment on the public hearing of the German Bundestag’s Committee on Health “Better guarantee of safety, efficacy and health benefit of medical devices”, Bundestag printed paper 17/8920, and “More safety for medical devices”, Bundestag printed paper 17/9932 (German version)

2012-06-06

Comment on the draft of a second law to Change Legislation on Medicinal Products and Other Regulations. (16th Amendment to the Medicinal Products Act [AMG]) (German version)

2012-03-07

Joint statement from IQWiG, GMDS and IBS-DR: "Importance of results from indirect comparisons"

2012-01-04

Comment on the draft of the Second law to Change Legislation on Medicinal Products and Other Regulations (16th Amendment to the AMG) (German version)